Like other cytotoxic cancer therapies, immunotherapy promotes inflammation within the TME, which can include cytokine release syndrome characterized by hypersecretion of pro-inflammatory cytokines, including IL-6, IL-1, TNFα, IL-5, IL-10, IFN, and TGFs by various immune cells (72). Here, IL1B is linked to cancer.